Changes and its significance in the expression of serum miR-324-5p in patients with depression treated by agomelatine combined with hyperbaric oxygen
10.3760/cma.j.cn311847-20210430-00138
- VernacularTitle:阿戈美拉汀联合高压氧治疗抑郁症患者血清miR-324-5p表达量的变化及意义
- Author:
Yujie MENG
1
;
Jing LIN
1
;
Yuhuan LI
1
Author Information
1. 260034 山东省青岛，青岛市精神卫生中心
- Publication Type:Journal Article
- Keywords:
Depression;
Agomelatine;
Hyperbaric oxygen;
MicroRNA-324-5p;
Clinical efficacy
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2021;28(6):749-753,766
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the changes and its significance in the expression of serum microRNA-324-5p (miR-324-5p) in patients with depression treated by agomelatine combined with hyperbaric oxygen (HBO).Methods:A total of 122 patients with depression treated in the Qingdao Mental Health Center from March 2019 to December 2020 were selected as the research subjects (depression group), and another 50 healthy people who had health check-ups during the same period were included in the control group. After the combined treatment of agomelatine and HBO, the patients were divided into effective group ( n=91) and ineffective group ( n=31) based on the clinical efficacy. The expression level of miR-324-5p was detected by real-time fluorescence quantitative PCR, and the efficacy of miR-324-5p was predicted by receiver operating characteristics (ROC) curve. The relationship between miR-324-5p and clinical efficacy was analyzed by logistic regression, and the dose-response relationship between miR-324-5p and the clinical efficacy was analyzed by logistic regression with restriction cubic splines. Results:The relative expression levels of miR-324-5p in both groups after treatment were higher than those before treatment; the relative expression level of miR-324-5p in the ineffective group was lower than that in the effective group; and the differences were statistically significant ( P<0.05). After 1∶1 propensity score matching (PSM), the relative expression level of miR-324-5p in the effective group after treatment was higher than that before treatment; the relative expression level of miR-324-5p in the ineffective group was lower than that in the effective group; and the differences were statistically significant ( P<0.05). Hamilton depression scale (HADM) score was an independent risk factor for the clinical efficacy of depression ( P<0.05), and post-treatment miR-324-5p was an independent protective factor for the clinical efficacy of depression ( P<0.05). The area under the ROC curve, the optimal cut-point, sensitivity, and specificity of the ROC curve predicting the clinical efficacy of miR-324-5p were 0.778 (95% CI: 0.589-0.908), 0.72, 53.33%, and 100.00%, respectively. After treatment, miR-324-5p was associated with the clinical efficacy of depression ( χ2=9.26, P=0.026), demonstrating a non-linear relationship ( χ2=8.24, P=0.016). Taking the optimal cut-point of miR-324-5p after treatment predicting the clinical efficacy of depression as a reference point, the risk of treatment ineffectiveness was high when post-treatment miR-324-5p was less than 0.72, the risk of treatment ineffectiveness was low when post-treatment miR-324-5p was higher than 0.72. Conclusion:The relative low expression of miR-324-5p in patients with depression after agomelatine combined with HBO treatment is related to poor clinical efficacy.
